POTASSIUM PHOSPHATES
Clinical safety rating
cautionComprehensive clinical and safety monograph for POTASSIUM PHOSPHATES (POTASSIUM PHOSPHATES).
Phosphate ion is essential for energy metabolism, buffer systems, and bone mineralization. Potassium is a critical intracellular cation for nerve conduction, muscle contraction, and acid-base balance. Coadministration restores electrolyte balance and provides phosphate for cellular function.
| Metabolism | Phosphate is primarily excreted by the kidneys. Potassium is also mainly eliminated renally. There is no hepatic metabolism of the salts. |
| Excretion | Renal: approximately 90% as phosphate (reabsorbed variably depending on dietary intake and parathyroid hormone activity). Fecal: <10%. |
| Half-life | Not applicable as a drug; endogenous phosphate has a terminal elimination half-life of 6-8 hours in the setting of renal impairment, but is not clinically significant in normal physiology. |
| Protein binding | Approximately 10-20% bound to albumin; remainder is free or complexed with cations. |
| Volume of Distribution | 0.15-0.25 L/kg; reflects distribution primarily in extracellular fluid and bone (major storage site). |
| Bioavailability | Oral: 60-70% (varies with renal function and vitamin D status). |
| Onset of Action | IV: Immediate (within minutes) for correction of hypophosphatemia. Oral: 2-4 hours for measurable serum phosphate increase. |
| Duration of Action | IV: 4-6 hours for therapeutic effect on serum phosphate levels. Oral: 6-8 hours for sustained increase. |
| Molecular Weight | 174.18 |
20-40 mEq elemental phosphorus intravenously over 4-6 hours, typically in adults; dose expressed in mmol phosphate: 10-15 mmol phosphate IV over 4 hours. Oral: 1-2 g (250-500 mg elemental phosphorus) 4 times daily.
| Dosage form | SOLUTION |
| Renal impairment | Contraindicated in severe renal impairment (eGFR <30 mL/min/1.73m2) due to risk of hyperphosphatemia; adjust based on serum phosphate levels; reduce dose or increase interval in moderate impairment (eGFR 30-59 mL/min/1.73m2). |
| Liver impairment | No specific Child-Pugh based adjustments; caution in severe hepatic dysfunction due to potential electrolyte imbalances; monitor serum phosphate and calcium. |
| Pediatric use | IV: 0.5-1.5 mmol phosphate/kg over 4-6 hours (max 15 mmol/dose); oral: 2-3 mmol phosphate/kg/day divided q6h. Doses based on phosphorus needs. |
| Geriatric use | Start at lower end of dosing range due to age-related renal function decline; monitor renal function and serum phosphate closely; adjust intervals if creatinine clearance <50 mL/min. |
| 1st trimester | Potassium phosphates are essential electrolytes; supplementation is generally considered safe when used at recommended doses. However, use only if clearly needed due to potential for electrolyte imbalances. |
| 2nd trimester | Similarly safe as in first trimester; monitor serum phosphate and potassium levels to avoid hyperphosphatemia or hyperkalemia. |
| 3rd trimester | Use with caution; high doses may cause maternal electrolyte disturbances that could affect fetal acid-base balance. |
Clinical note
Comprehensive clinical and safety monograph for POTASSIUM PHOSPHATES (POTASSIUM PHOSPHATES).
| Placental transfer | Both potassium and phosphate ions cross the placenta via active transport and diffusion, maintaining fetal-maternal gradients. Placental transfer is regulated to meet fetal needs. |
| Breastfeeding | Potassium and phosphate are normal constituents of breast milk. Supplementation at recommended doses is considered compatible with breastfeeding, but monitor infant for signs of electrolyte imbalance if maternal doses are high. |
| Lactation Rating | L2 (Limited data - probably compatible) |
| Teratogenic Risk | No teratogenic effects reported in human studies. Potassium phosphate is FDA Pregnancy Category C. Inadequate data in pregnant women. Animal studies not available. Use only if clearly needed. |
| Fetal Monitoring | Monitor serum potassium, phosphorus, calcium, magnesium, and creatinine. Assess for signs of hyperphosphatemia, hypocalcemia, and hyperkalemia. ECG monitoring recommended with rapid infusion or high doses. |
| Fertility Effects | No data on effects on fertility in humans. Animal studies not available. |
■ FDA Black Box Warning
None.
| Serious Effects |
HyperphosphatemiaHyperkalemiaSevere renal impairmentHypocalcemia
| Precautions | Use with caution in patients with renal impairment, cardiac disease, hyperkalemia, hyperphosphatemia, hypocalcemia, or dehydration. Monitor serum potassium, phosphate, calcium, and renal function regularly. Avoid rapid infusion due to risk of cardiac arrhythmias. |
| Food/Dietary | Avoid high-potassium foods (e.g., bananas, oranges, potatoes, spinach) and high-phosphate foods (e.g., dairy products, nuts, seeds, cola) unless otherwise instructed. Excessive intake may lead to electrolyte imbalances, especially in renal impairment. |
| Clinical Pearls | Must be diluted before IV administration; undiluted solution can cause cardiac arrest. Incompatible with calcium-containing solutions; can form calcium phosphate precipitates. Monitor serum phosphate and calcium levels closely, especially in renal impairment. IV infusion rate should not exceed 10 mmol/h to avoid hyperphosphatemia-induced hypocalcemia. Use with caution in patients with hyperkalemia as potassium phosphate contributes potassium load. |
| Patient Advice | Do not take other potassium or phosphate supplements unless directed by your healthcare provider. · Inform your doctor if you have kidney disease, heart disease, or high potassium levels. · Report symptoms of high potassium such as muscle weakness, irregular heartbeat, or tingling sensation. · This medication may be given intravenously; do not mix with calcium-containing solutions. · Adhere to dietary restrictions as advised to avoid excessive potassium or phosphate intake. |
Loading safety data…